36. Epidermolysis bullosa Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 163 / Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125
Drugs and their primary sponsors and trial info
3400930060797
CHU NICE
2020 Phase 2 EUCTR2020-001542-19-FR France;
ABH001
Shire Regenerative Medicine, Inc.
2013 - EUCTR2012-001815-21-PT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-ES Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-DE Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-AT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
2012 Phase 3 NCT01749306 Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
AC-203
TWi Biotechnology, Inc.
2018 Phase 2 NCT03468322 Taiwan;
AGLE 102
Aegle Therapeutics
2022 Phase 1/Phase 2 NCT04173650 -
ALLANTOINA
SCIODERM, INC
- Phase 3 EUCTR2014-005679-96-IT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
ALLO-ASC-DFU
Anterogen Co., Ltd.
2017 - NCT03183934 Korea, Republic of;
AVCN583601 ( Cannabidiol cream)
Elena Pope
2020 Phase 2/Phase 3 NCT04613102 Canada;
Alemtuzumab
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Allo-APZ2-EB
RHEACELL GmbH & Co. KG
2019 Phase 1;Phase 2 EUCTR2018-001009-98-FR Austria;France;Germany;United Kingdom;United States;
2019 Phase 1;Phase 2 EUCTR2018-001009-98-DE Austria;France;Germany;Italy;United Kingdom;United States;
2019 Phase 1/Phase 2 NCT03529877 Austria;France;Germany;Italy;United Kingdom;United States;
2019 Phase 1 EUCTR2018-001009-98-IT Austria;France;Germany;Italy;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-001009-98-GB Austria;France;Germany;Italy;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-001009-98-AT Austria;France;Germany;Italy;United Kingdom;United States;
Allogeneic adipose tissue-derived MSC
Masarykova univerzita
- Phase 1;Phase 2 EUCTR2020-002936-55-CZ Czech Republic;
Allogeneic mesenchymal stromal cells
King's College London
2015 Phase 1;Phase 2 EUCTR2014-004500-30-GB United Kingdom;
Allogeneic skin-derived ABCB5-positive mesenchymal stem cells
RHEACELL GmbH & Co. KG
2019 Phase 1;Phase 2 EUCTR2018-001009-98-FR Austria;France;Germany;United Kingdom;United States;
2019 Phase 1;Phase 2 EUCTR2018-001009-98-DE Austria;France;Germany;Italy;United Kingdom;United States;
2019 Phase 1 EUCTR2018-001009-98-IT Austria;France;Germany;Italy;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-001009-98-GB Austria;France;Germany;Italy;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-001009-98-AT Austria;France;Germany;Italy;United Kingdom;United States;
Allogenic mesenchymal stromal cells
King's College London
2012 Phase 1;Phase 2 EUCTR2012-001394-87-GB United Kingdom;
Alwextin cream
Northwestern University
2009 Phase 2 NCT00825565 United States;
Anti-thymocyte globulin
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
BIOOPA dressing
Medical University of Warsaw
2020 Phase 1;Phase 2 EUCTR2018-003890-91-PL Poland;
Blood test
Assistance Publique - Hôpitaux de Paris
2017 - NCT03730584 France;
Bone marrow infusion
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
Bone marrow or umbilical cord blood (UCG) stem cell transplantation
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
Botulinic toxin
University Hospital, Toulouse
2018 Phase 2/Phase 3 NCT03453632 France;
Busilvex
Universitair Medisch Centrum Utrecht
2014 Phase 2 EUCTR2012-000605-72-NL Netherlands;
Busulfan
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
2007 - NCT00478244 United States;
CCP-020
Castle Creek Pharmaceuticals, LLC
2018 Phase 1 EUCTR2018-000439-29-GB France;Germany;Netherlands;United Kingdom;United States;
- Phase 1 EUCTR2018-000439-29-NL France;Germany;Netherlands;United Kingdom;United States;
COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin
Institut National de la Santé Et de la Recherche Médicale, France
2020 Phase 1/Phase 2 NCT04186650 France;
CX501
CELLERIX, S.A.
2006 - EUCTR2005-002329-30-ES Spain;
Tigenix S.A.U.
2006 Phase 2 NCT00987142 Spain;
Cannabinol (CBN)
InMed Pharmaceuticals Inc.
2022 Phase 2 EUCTR2021-000214-42-ES Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain;
2021 Phase 2 EUCTR2021-000214-42-GR Austria;France;Germany;Greece;Israel;Italy;Serbia;
2021 Phase 2 EUCTR2021-000214-42-AT Austria;France;Germany;Greece;Israel;Italy;Serbia;
- Phase 2 EUCTR2021-000214-42-FR Austria;France;Germany;Greece;Israel;Italy;Serbia;
- Phase 2 EUCTR2021-000214-42-DE Austria;France;Germany;Greece;Israel;Italy;Serbia;
Cell transplantation
Royan Institute
2010 Phase 1 NCT01908088 Iran, Islamic Republic of;
Cultured allogeneic fibroblasts
Intercytex Ltd
2011 Phase 2 EUCTR2010-023121-38-GB United Kingdom;
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
2010 Phase 2 NCT01033552 United States;
2007 - NCT00478244 United States;
Cyclosporine A
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
Células madre mesenquimales haploidénticas derivadas de médula ósea
Fundación para la Investigación Biomédica Hospital Universitario La Paz
2017 Phase 1 EUCTR2017-000606-37-ES Spain;
Diacerein Ointment
Castle Creek Pharmaceuticals, LLC
2018 Phase 1 NCT03472287 France;Netherlands;United Kingdom;United States;
Diacerein ointment
Castle Creek Pharmaceuticals, LLC
2017 Phase 2 NCT03389308 United States;
2017 Phase 2 NCT03154333 Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States;
Diacerin cream
Tel-Aviv Sourasky Medical Center
2015 Phase 2 NCT02470689 -
Donor mesenchymal stem cell infusions
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
Dysport
Sophiahemmet
2009 - EUCTR2009-010763-17-SE Sweden;
Dysport® (Botulinumtoxin A (Btx A))
Uppsala University
2009 Phase 2 NCT00936533 Sweden;
EB-101
Abeona Therapeutics, Inc
2020 Phase 3 NCT04227106 United States;
Jean Yuh Tang
2018 Phase 3 NCT03632265 -
Episalvan gel
Amryt Research Limited
2018 Phase 3 EUCTR2016-002066-32-HU Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-HR Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-DK Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-BE Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-IT Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-IE Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-GR Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-GB Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-ES Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-AT Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
- Phase 3 EUCTR2016-002066-32-DE Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
- Phase 3 EUCTR2016-002066-32-CZ Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
Erythrocine oral
CHU de NICE
- Phase 2 EUCTR2010-024428-10-FR France;
Erythromycine
CHU de NICE
- Phase 2 EUCTR2010-024428-10-FR France;
Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA.
HOLOSTEM TERAPIE AVANZATE S.R.L.
2021 Phase 2;Phase 3 EUCTR2018-000261-36-IT France;Germany;Italy;
FCX-007 (dabocemagene autoficel
Castle Creek Biosciences, LLC.
2020 Phase 3 NCT04213261 United States;
Fludarabine
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
2010 Phase 2 NCT01033552 United States;
Fludarabine phosphate
Masonic Cancer Center, University of Minnesota
2007 - NCT00478244 United States;
Gene-modified autologous fibroblasts
King's College London
2015 Phase 1 NCT02493816 United Kingdom;
Genetically corrected cultured epidermal autograft (ATMP)
Holostem Terapie Avanzate s.r.l.
2017 Phase 1/Phase 2 NCT02984085 Austria;
Gentamicin
University of Southern California
2018 Phase 1/Phase 2 NCT03392909 United States;
2016 Phase 1/Phase 2 NCT02698735 -
Gentamicin Sulfate
Oslo University Hospital
2020 Phase 1/Phase 2 NCT04644627 Norway;
University of Southern California
2018 Phase 1/Phase 2 NCT03526159 United States;
2017 Phase 1/Phase 2 NCT03012191 United States;
Gentamicin Sulfate, Injectable
University of Southern California
2019 Phase 1/Phase 2 NCT04140786 United States;
Gentamicin sulfate ointment
Oslo University Hospital
2020 Phase 2 EUCTR2020-002337-15-NO Norway;
Granulocyte Colony Stimulating Factor (GCSF)
Vanderbilt University Medical Center
2012 Phase 2 NCT01538862 United States;
HOLOGENE17
Holostem Terapie Avanzate s.r.l.
2017 Phase 1;Phase 2 EUCTR2016-000095-17-AT Austria;
HOLOGENE7
Holostem Terapie Avanzate s.r.l.
2016 Phase 1;Phase 2 EUCTR2015-004592-74-AT Austria;
HP802-247
Healthpoint
2012 Phase 2 NCT01528306 United States;
Hematopoietic bone marrow transplantation
Masonic Cancer Center, University of Minnesota
2007 - NCT00478244 United States;
Hologene 5 DS
HOLOSTEM TERAPIE AVANZATE S.R.L.
2021 Phase 2;Phase 3 EUCTR2018-000261-36-IT France;Germany;Italy;
Human Allogeneic WJ-MSCs
Medical University of Warsaw
2020 Phase 1;Phase 2 EUCTR2018-003890-91-PL Poland;
Human Umbilical Cord Blood-derived Mesenchymal Stem Cells
Gangnam Severance Hospital
2016 Phase 1/Phase 2 NCT04520022 Korea, Republic of;
Human allogeneic adipose tissue-derived mesenchymal stem cells expanded
Masarykova univerzita
- Phase 1;Phase 2 EUCTR2020-002936-55-CZ Czech Republic;
Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh
Shire Regenerative Medicine, Inc.
2013 - EUCTR2012-001815-21-PT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-ES Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-DE Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-AT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
Human fibroblast-derived dermal substitute, Dermagraft
Shire Regenerative Medicine, Inc.
2013 - EUCTR2012-001815-21-PT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-ES Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-DE Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-AT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
ICX-RHY-013
Intercytex Ltd
2011 Phase 2 EUCTR2010-023121-38-GB United Kingdom;
INM-755
InMed Pharmaceuticals Inc.
2022 Phase 2 EUCTR2021-000214-42-ES Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain;
2021 Phase 2 EUCTR2021-000214-42-GR Austria;France;Germany;Greece;Israel;Italy;Serbia;
2021 Phase 2 EUCTR2021-000214-42-AT Austria;France;Germany;Greece;Israel;Italy;Serbia;
- Phase 2 EUCTR2021-000214-42-FR Austria;France;Germany;Greece;Israel;Italy;Serbia;
- Phase 2 EUCTR2021-000214-42-DE Austria;France;Germany;Greece;Israel;Italy;Serbia;
INM-755 (cannabinol) cream
InMed Pharmaceuticals Inc.
2021 Phase 2 NCT04908215 -
Infectogenta
Oslo University Hospital
2020 Phase 2 EUCTR2020-002337-15-NO Norway;
Isotretinoin
University of North Carolina
2000 Phase 1 NCT00014729 -
Ixekizumab
CHU NICE
2020 Phase 2 EUCTR2020-001542-19-FR France;
Jojoba oil with broccoli sprout extract
Johns Hopkins University
2015 Phase 1 NCT02592954 United States;
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Stanford University
2010 Phase 1/Phase 2 NCT01263379 United States;
Lorazepam
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Losartan HEXAL
Medical Center - University of Freiburg
2017 Phase 2 EUCTR2015-003670-32-AT Austria;Germany;
- Phase 2 EUCTR2015-003670-32-DE Austria;Germany;
MESENCHYMAL STEM CELLS (MSCS)
Fundación para la Investigación Biomédica Hospital Universitario La Paz
2017 Phase 1 EUCTR2017-000606-37-ES Spain;
Mesenchymal Stem Cells extracted from bone marrow
Fundación para la Investigación Biomédica Hospital Universitario La Paz
2017 Phase 1 EUCTR2017-000606-37-ES Spain;
Mesenchymal Stromal Cells
Ishin Pharmaceutical Co. Ltd.
2017 Phase 1,2 JPRN-UMIN000028366 Japan;
Mesenchymal stem cell transplantation
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
Mesenchymal stem cells derived from bone marrow (BM-MSCs)
Instituto de Investigación Hospital Universitario La Paz
2018 Phase 1/Phase 2 NCT04153630 Spain;
Methoxsalen
National Center for Research Resources (NCRR)
1996 Phase 2 NCT00004359 -
Morphine sulphate in intrasite gel
Institute of Child Health
2005 Phase 4 NCT00231517 United Kingdom;
Mycophenolate mofetil
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
Normal saline
Phoenix Tissue Repair, Inc.
2019 Phase 1/Phase 2 NCT03752905 United States;
Occlusive non adherent dressing
Tigenix S.A.U.
2006 Phase 2 NCT00987142 Spain;
Oleogel-S10
Amryt Research Limited
2018 Phase 3 EUCTR2016-002066-32-HU Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-HR Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-DK Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-BE Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2017 Phase 3 NCT03068780 Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-IT Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-IE Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-GR Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-GB Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-ES Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-AT Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
- Phase 3 EUCTR2016-002066-32-DE Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
- Phase 3 EUCTR2016-002066-32-CZ Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
Open Label Topical Beremagene Geperpavec (B-VEC)
Krystal Biotech, Inc.
2021 Phase 3 NCT04917874 United States;
Oral erythromycin
Centre Hospitalier Universitaire de Nice
2011 Phase 3 NCT01340235 France;
POLYPHENON E
CHU de NICE
2010 - EUCTR2009-012750-21-FR France;
PTR-01
Phoenix Tissue Repair, Inc.
2020 Phase 2 NCT04599881 United States;
2019 Phase 1/Phase 2 NCT03752905 United States;
Palifermin
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Polyphenon E
Centre Hospitalier Universitaire de Nice
2010 Phase 2 NCT00951964 France;
Pregabalin
The Hospital for Sick Children
2019 Phase 3 NCT03928093 Canada;
Psorcutan-Ointment
Universitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität Salzburg
2016 Phase 2 EUCTR2016-001967-35-AT Austria;
QR-313
Phoenicis Therapeutics
2018 Phase 1/Phase 2 NCT03605069 France;Spain;United States;
QR-313 Gel for Topical (Cutaneous) Administration
ProQR Therapeutics
- Phase 1;Phase 2 EUCTR2017-004806-17-FR Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
ProQR Theraputics
2018 Phase 1;Phase 2 EUCTR2017-004806-17-ES Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
Wings Therapeutics Inc.
2018 Phase 1;Phase 2 EUCTR2017-004806-17-GB Czech Republic;France;Germany;Spain;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-004806-17-DE Czech Republic;France;Germany;Spain;United Kingdom;United States;
- Phase 1;Phase 2 EUCTR2017-004806-17-CZ Czech Republic;France;Germany;Spain;United Kingdom;United States;
REGE pro dressing
Egyptian Atomic Energy Authority
2017 - NCT03942250 Egypt;
RGN-137
Lenus Therapeutics, LLC
2019 Phase 2 NCT03578029 United States;
Rigosertib
Gemeinn. Salzburger Landeskliniken BetriebsGesmbH, University Hospital for Dermatology, EB-House Austria
2017 Phase 2 EUCTR2016-003832-19-AT Austria;
Rigosertib Oral Capsules / Rigosertib Intravenous
Prof. Johann Bauer
2021 Phase 1/Phase 2 NCT03786237 Austria;
Rigosertib Sodium
Thomas Jefferson University
2021 Early Phase 1 NCT04177498 United States;
Rituximab
Research group of rare intractable dermatologial disorder
2010 Phase 2 JPRN-UMIN000004428 Japan;
Ropivacaine
Assistance Publique - Hôpitaux de Paris
2017 - NCT03730584 France;
SASS
CHU de Quebec-Universite Laval
2019 Early Phase 1 NCT04171661 Canada;
SD-101
Scioderm INC, An Amicus Therapeutics Company
- Phase 3 EUCTR2014-002288-14-BE Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, An Amicus Therapeutics Company
2016 Phase 3 EUCTR2014-002288-14-LT Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-002288-14-PL Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-002288-14-DE Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-NL Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-GB Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-AT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, INC
2016 Phase 3 EUCTR2014-005679-96-ES Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-GB Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-AT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 - EUCTR2014-005679-96-NL Australia;Austria;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Scioderm, INC, An Amicus Therapeutics Company
2017 Phase 3 EUCTR2014-005679-96-LT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-DE Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
- Phase 3 EUCTR2014-005679-96-PL Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, INC.
2016 Phase 3 EUCTR2014-002288-14-ES Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-IT Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
SD-101 Dermal Cream ()
Scioderm, Inc.
2014 Phase 2 NCT02014376 United States;
SD-101 dermal cream ()
Scioderm, Inc.
2014 Phase 2 NCT02090283 United States;
2014 Phase 2 NCT02014376 United States;
SD-101-6.0 cream
Scioderm, Inc.
2015 Phase 3 NCT02670330 Australia;Austria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 NCT02384460 Australia;Austria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
SIN LV Mediated ex vivo transduced autologous fibroblasts expressing codon-optimised COL7A1
King's College London
2016 Phase 1 EUCTR2014-004884-19-GB United Kingdom;
SIN RV-mediated COL7A1 corrected autologous skin equivalent
INSERM
2019 Phase 1;Phase 2 EUCTR2016-002790-35-FR France;
See below for FCX-007 description)
Castle Creek Biosciences, LLC.
2020 Phase 3 NCT04213261 United States;
Sericare
Birken GmbH
2010 - EUCTR2010-019945-24-DE Germany;
Sericare®
Birken AG
2010 Phase 2 NCT01294241 Germany;
Serlopitant Tablet
Stanford University
2019 Phase 2 NCT03836001 United States;
SimpleCare
EB House Austria
2013 Phase 3 EUCTR2013-002034-21-AT Austria;
Sirolimus
Premier Specialists, Australia
2016 Phase 2 NCT03016715 Australia;
Sirolimus,
Stanford University
2016 Phase 2 NCT02960997 United States;
TC-MSC
King's College London
2015 Phase 1;Phase 2 EUCTR2014-004500-30-GB United Kingdom;
2012 Phase 1;Phase 2 EUCTR2012-001394-87-GB United Kingdom;
Universitair Medisch Centrum Utrecht
2014 Phase 2 EUCTR2012-000605-72-NL Netherlands;
Tacrolimus
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
Taltz
CHU NICE
2020 Phase 2 EUCTR2020-001542-19-FR France;
Tetracyclin
Rambam Health Care Campus
2006 Phase 4 NCT00336154 Israel;
Thymoglobulin
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
TolaSure Topical Gel
BioMendics, LLC
2021 Phase 1 NCT05062070 United States;
Topical BPM31510 Cream
Shasa Hu
2016 Phase 1 NCT02793960 United States;
Topical Beremagene Geperpavec
Krystal Biotech, Inc.
2020 Phase 3 NCT04491604 United States;
Topical beremagene geperpavec
Krystal Biotech, Inc.
2018 Phase 2 NCT03536143 United States;
Topical opiod
Institute of Child Health
2005 Phase 4 NCT00231517 United Kingdom;
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL17A1-encoding retroviral vector
Holostem Terapie Avanzate s.r.l.
2017 Phase 1;Phase 2 EUCTR2016-000095-17-AT Austria;
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL7A1-encoding retroviral vector, obtained from secondary culture of ex vivo expanded autologous human keratinocytes.
Holostem Terapie Avanzate s.r.l.
2016 Phase 1;Phase 2 EUCTR2015-004592-74-AT Austria;
Transplantation
Holostem Terapie Avanzate s.r.l.
2022 Phase 2/Phase 3 NCT05111600 France;Germany;Italy;
Transvamix (100mg/mL THC, 50mg/mL CBD)
University Medical Center Groningen
- Phase 2 EUCTR2021-000103-20-NL Netherlands;
Trimethoprim
The Hospital for Sick Children
2006 Phase 2 NCT00380640 Canada;
Triterpene dry extract from birch cork
Birken GmbH
2010 - EUCTR2010-019945-24-DE Germany;
Unavailable
ProQR Therapeutics
- Phase 1;Phase 2 EUCTR2017-004806-17-FR Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
ProQR Theraputics
2018 Phase 1;Phase 2 EUCTR2017-004806-17-ES Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
Wings Therapeutics Inc.
2018 Phase 1;Phase 2 EUCTR2017-004806-17-GB Czech Republic;France;Germany;Spain;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-004806-17-DE Czech Republic;France;Germany;Spain;United Kingdom;United States;
- Phase 1;Phase 2 EUCTR2017-004806-17-CZ Czech Republic;France;Germany;Spain;United Kingdom;United States;
VPD-737
Jean Yuh Tang
2016 Phase 2 NCT02654483 United States;
Vehicle
Premier Specialists, Australia
2016 Phase 2 NCT03016715 Australia;
Stanford University
2016 Phase 2 NCT02960997 United States;
TWi Biotechnology, Inc.
2018 Phase 2 NCT03468322 Taiwan;
Vehicle (SD-101 )
Scioderm, Inc.
2014 Phase 2 NCT02014376 United States;
Vehicle Cream
InMed Pharmaceuticals Inc.
2021 Phase 2 NCT04908215 -
Vehicle Topical Gel
BioMendics, LLC
2021 Phase 1 NCT05062070 United States;
WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS
Medical University of Warsaw
2020 Phase 1;Phase 2 EUCTR2018-003890-91-PL Poland;
Zorblisa
Scioderm INC, An Amicus Therapeutics Company
- Phase 3 EUCTR2014-002288-14-BE Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, An Amicus Therapeutics Company
2016 Phase 3 EUCTR2014-002288-14-LT Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-002288-14-PL Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-002288-14-DE Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-NL Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-GB Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-AT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, INC
2016 Phase 3 EUCTR2014-005679-96-ES Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-GB Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-AT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 - EUCTR2014-005679-96-NL Australia;Austria;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Scioderm, INC, An Amicus Therapeutics Company
2017 Phase 3 EUCTR2014-005679-96-LT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-DE Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
- Phase 3 EUCTR2014-005679-96-PL Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, INC.
2016 Phase 3 EUCTR2014-002288-14-ES Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-IT Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
CHU NICE
2020 Phase 2 EUCTR2020-001542-19-FR France;
ABH001
Shire Regenerative Medicine, Inc.
2013 - EUCTR2012-001815-21-PT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-ES Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-DE Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-AT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
2012 Phase 3 NCT01749306 Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
AC-203
TWi Biotechnology, Inc.
2018 Phase 2 NCT03468322 Taiwan;
AGLE 102
Aegle Therapeutics
2022 Phase 1/Phase 2 NCT04173650 -
ALLANTOINA
SCIODERM, INC
- Phase 3 EUCTR2014-005679-96-IT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
ALLO-ASC-DFU
Anterogen Co., Ltd.
2017 - NCT03183934 Korea, Republic of;
AVCN583601 ( Cannabidiol cream)
Elena Pope
2020 Phase 2/Phase 3 NCT04613102 Canada;
Alemtuzumab
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Allo-APZ2-EB
RHEACELL GmbH & Co. KG
2019 Phase 1;Phase 2 EUCTR2018-001009-98-FR Austria;France;Germany;United Kingdom;United States;
2019 Phase 1;Phase 2 EUCTR2018-001009-98-DE Austria;France;Germany;Italy;United Kingdom;United States;
2019 Phase 1/Phase 2 NCT03529877 Austria;France;Germany;Italy;United Kingdom;United States;
2019 Phase 1 EUCTR2018-001009-98-IT Austria;France;Germany;Italy;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-001009-98-GB Austria;France;Germany;Italy;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-001009-98-AT Austria;France;Germany;Italy;United Kingdom;United States;
Allogeneic adipose tissue-derived MSC
Masarykova univerzita
- Phase 1;Phase 2 EUCTR2020-002936-55-CZ Czech Republic;
Allogeneic mesenchymal stromal cells
King's College London
2015 Phase 1;Phase 2 EUCTR2014-004500-30-GB United Kingdom;
Allogeneic skin-derived ABCB5-positive mesenchymal stem cells
RHEACELL GmbH & Co. KG
2019 Phase 1;Phase 2 EUCTR2018-001009-98-FR Austria;France;Germany;United Kingdom;United States;
2019 Phase 1;Phase 2 EUCTR2018-001009-98-DE Austria;France;Germany;Italy;United Kingdom;United States;
2019 Phase 1 EUCTR2018-001009-98-IT Austria;France;Germany;Italy;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-001009-98-GB Austria;France;Germany;Italy;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-001009-98-AT Austria;France;Germany;Italy;United Kingdom;United States;
Allogenic mesenchymal stromal cells
King's College London
2012 Phase 1;Phase 2 EUCTR2012-001394-87-GB United Kingdom;
Alwextin cream
Northwestern University
2009 Phase 2 NCT00825565 United States;
Anti-thymocyte globulin
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
BIOOPA dressing
Medical University of Warsaw
2020 Phase 1;Phase 2 EUCTR2018-003890-91-PL Poland;
Blood test
Assistance Publique - Hôpitaux de Paris
2017 - NCT03730584 France;
Bone marrow infusion
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
Bone marrow or umbilical cord blood (UCG) stem cell transplantation
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
Botulinic toxin
University Hospital, Toulouse
2018 Phase 2/Phase 3 NCT03453632 France;
Busilvex
Universitair Medisch Centrum Utrecht
2014 Phase 2 EUCTR2012-000605-72-NL Netherlands;
Busulfan
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
2007 - NCT00478244 United States;
CCP-020
Castle Creek Pharmaceuticals, LLC
2018 Phase 1 EUCTR2018-000439-29-GB France;Germany;Netherlands;United Kingdom;United States;
- Phase 1 EUCTR2018-000439-29-NL France;Germany;Netherlands;United Kingdom;United States;
COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin
Institut National de la Santé Et de la Recherche Médicale, France
2020 Phase 1/Phase 2 NCT04186650 France;
CX501
CELLERIX, S.A.
2006 - EUCTR2005-002329-30-ES Spain;
Tigenix S.A.U.
2006 Phase 2 NCT00987142 Spain;
Cannabinol (CBN)
InMed Pharmaceuticals Inc.
2022 Phase 2 EUCTR2021-000214-42-ES Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain;
2021 Phase 2 EUCTR2021-000214-42-GR Austria;France;Germany;Greece;Israel;Italy;Serbia;
2021 Phase 2 EUCTR2021-000214-42-AT Austria;France;Germany;Greece;Israel;Italy;Serbia;
- Phase 2 EUCTR2021-000214-42-FR Austria;France;Germany;Greece;Israel;Italy;Serbia;
- Phase 2 EUCTR2021-000214-42-DE Austria;France;Germany;Greece;Israel;Italy;Serbia;
Cell transplantation
Royan Institute
2010 Phase 1 NCT01908088 Iran, Islamic Republic of;
Cultured allogeneic fibroblasts
Intercytex Ltd
2011 Phase 2 EUCTR2010-023121-38-GB United Kingdom;
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
2010 Phase 2 NCT01033552 United States;
2007 - NCT00478244 United States;
Cyclosporine A
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
Células madre mesenquimales haploidénticas derivadas de médula ósea
Fundación para la Investigación Biomédica Hospital Universitario La Paz
2017 Phase 1 EUCTR2017-000606-37-ES Spain;
Diacerein Ointment
Castle Creek Pharmaceuticals, LLC
2018 Phase 1 NCT03472287 France;Netherlands;United Kingdom;United States;
Diacerein ointment
Castle Creek Pharmaceuticals, LLC
2017 Phase 2 NCT03389308 United States;
2017 Phase 2 NCT03154333 Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States;
Diacerin cream
Tel-Aviv Sourasky Medical Center
2015 Phase 2 NCT02470689 -
Donor mesenchymal stem cell infusions
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
Dysport
Sophiahemmet
2009 - EUCTR2009-010763-17-SE Sweden;
Dysport® (Botulinumtoxin A (Btx A))
Uppsala University
2009 Phase 2 NCT00936533 Sweden;
EB-101
Abeona Therapeutics, Inc
2020 Phase 3 NCT04227106 United States;
Jean Yuh Tang
2018 Phase 3 NCT03632265 -
Episalvan gel
Amryt Research Limited
2018 Phase 3 EUCTR2016-002066-32-HU Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-HR Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-DK Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-BE Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-IT Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-IE Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-GR Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-GB Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-ES Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-AT Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
- Phase 3 EUCTR2016-002066-32-DE Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
- Phase 3 EUCTR2016-002066-32-CZ Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
Erythrocine oral
CHU de NICE
- Phase 2 EUCTR2010-024428-10-FR France;
Erythromycine
CHU de NICE
- Phase 2 EUCTR2010-024428-10-FR France;
Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA.
HOLOSTEM TERAPIE AVANZATE S.R.L.
2021 Phase 2;Phase 3 EUCTR2018-000261-36-IT France;Germany;Italy;
FCX-007 (dabocemagene autoficel
Castle Creek Biosciences, LLC.
2020 Phase 3 NCT04213261 United States;
Fludarabine
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
2010 Phase 2 NCT01033552 United States;
Fludarabine phosphate
Masonic Cancer Center, University of Minnesota
2007 - NCT00478244 United States;
Gene-modified autologous fibroblasts
King's College London
2015 Phase 1 NCT02493816 United Kingdom;
Genetically corrected cultured epidermal autograft (ATMP)
Holostem Terapie Avanzate s.r.l.
2017 Phase 1/Phase 2 NCT02984085 Austria;
Gentamicin
University of Southern California
2018 Phase 1/Phase 2 NCT03392909 United States;
2016 Phase 1/Phase 2 NCT02698735 -
Gentamicin Sulfate
Oslo University Hospital
2020 Phase 1/Phase 2 NCT04644627 Norway;
University of Southern California
2018 Phase 1/Phase 2 NCT03526159 United States;
2017 Phase 1/Phase 2 NCT03012191 United States;
Gentamicin Sulfate, Injectable
University of Southern California
2019 Phase 1/Phase 2 NCT04140786 United States;
Gentamicin sulfate ointment
Oslo University Hospital
2020 Phase 2 EUCTR2020-002337-15-NO Norway;
Granulocyte Colony Stimulating Factor (GCSF)
Vanderbilt University Medical Center
2012 Phase 2 NCT01538862 United States;
HOLOGENE17
Holostem Terapie Avanzate s.r.l.
2017 Phase 1;Phase 2 EUCTR2016-000095-17-AT Austria;
HOLOGENE7
Holostem Terapie Avanzate s.r.l.
2016 Phase 1;Phase 2 EUCTR2015-004592-74-AT Austria;
HP802-247
Healthpoint
2012 Phase 2 NCT01528306 United States;
Hematopoietic bone marrow transplantation
Masonic Cancer Center, University of Minnesota
2007 - NCT00478244 United States;
Hologene 5 DS
HOLOSTEM TERAPIE AVANZATE S.R.L.
2021 Phase 2;Phase 3 EUCTR2018-000261-36-IT France;Germany;Italy;
Human Allogeneic WJ-MSCs
Medical University of Warsaw
2020 Phase 1;Phase 2 EUCTR2018-003890-91-PL Poland;
Human Umbilical Cord Blood-derived Mesenchymal Stem Cells
Gangnam Severance Hospital
2016 Phase 1/Phase 2 NCT04520022 Korea, Republic of;
Human allogeneic adipose tissue-derived mesenchymal stem cells expanded
Masarykova univerzita
- Phase 1;Phase 2 EUCTR2020-002936-55-CZ Czech Republic;
Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh
Shire Regenerative Medicine, Inc.
2013 - EUCTR2012-001815-21-PT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-ES Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-DE Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-AT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
Human fibroblast-derived dermal substitute, Dermagraft
Shire Regenerative Medicine, Inc.
2013 - EUCTR2012-001815-21-PT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-ES Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-DE Australia;Austria;Germany;Portugal;Spain;United States;
2013 - EUCTR2012-001815-21-AT Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
ICX-RHY-013
Intercytex Ltd
2011 Phase 2 EUCTR2010-023121-38-GB United Kingdom;
INM-755
InMed Pharmaceuticals Inc.
2022 Phase 2 EUCTR2021-000214-42-ES Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain;
2021 Phase 2 EUCTR2021-000214-42-GR Austria;France;Germany;Greece;Israel;Italy;Serbia;
2021 Phase 2 EUCTR2021-000214-42-AT Austria;France;Germany;Greece;Israel;Italy;Serbia;
- Phase 2 EUCTR2021-000214-42-FR Austria;France;Germany;Greece;Israel;Italy;Serbia;
- Phase 2 EUCTR2021-000214-42-DE Austria;France;Germany;Greece;Israel;Italy;Serbia;
INM-755 (cannabinol) cream
InMed Pharmaceuticals Inc.
2021 Phase 2 NCT04908215 -
Infectogenta
Oslo University Hospital
2020 Phase 2 EUCTR2020-002337-15-NO Norway;
Isotretinoin
University of North Carolina
2000 Phase 1 NCT00014729 -
Ixekizumab
CHU NICE
2020 Phase 2 EUCTR2020-001542-19-FR France;
Jojoba oil with broccoli sprout extract
Johns Hopkins University
2015 Phase 1 NCT02592954 United States;
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Stanford University
2010 Phase 1/Phase 2 NCT01263379 United States;
Lorazepam
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Losartan HEXAL
Medical Center - University of Freiburg
2017 Phase 2 EUCTR2015-003670-32-AT Austria;Germany;
- Phase 2 EUCTR2015-003670-32-DE Austria;Germany;
MESENCHYMAL STEM CELLS (MSCS)
Fundación para la Investigación Biomédica Hospital Universitario La Paz
2017 Phase 1 EUCTR2017-000606-37-ES Spain;
Mesenchymal Stem Cells extracted from bone marrow
Fundación para la Investigación Biomédica Hospital Universitario La Paz
2017 Phase 1 EUCTR2017-000606-37-ES Spain;
Mesenchymal Stromal Cells
Ishin Pharmaceutical Co. Ltd.
2017 Phase 1,2 JPRN-UMIN000028366 Japan;
Mesenchymal stem cell transplantation
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
Mesenchymal stem cells derived from bone marrow (BM-MSCs)
Instituto de Investigación Hospital Universitario La Paz
2018 Phase 1/Phase 2 NCT04153630 Spain;
Methoxsalen
National Center for Research Resources (NCRR)
1996 Phase 2 NCT00004359 -
Morphine sulphate in intrasite gel
Institute of Child Health
2005 Phase 4 NCT00231517 United Kingdom;
Mycophenolate mofetil
Masonic Cancer Center, University of Minnesota
2010 Phase 2 NCT01033552 United States;
Normal saline
Phoenix Tissue Repair, Inc.
2019 Phase 1/Phase 2 NCT03752905 United States;
Occlusive non adherent dressing
Tigenix S.A.U.
2006 Phase 2 NCT00987142 Spain;
Oleogel-S10
Amryt Research Limited
2018 Phase 3 EUCTR2016-002066-32-HU Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-HR Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-DK Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2018 Phase 3 EUCTR2016-002066-32-BE Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2017 Phase 3 NCT03068780 Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-IT Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-IE Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-GR Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-GB Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
2017 Phase 3 EUCTR2016-002066-32-ES Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002066-32-AT Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
- Phase 3 EUCTR2016-002066-32-DE Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
- Phase 3 EUCTR2016-002066-32-CZ Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
Open Label Topical Beremagene Geperpavec (B-VEC)
Krystal Biotech, Inc.
2021 Phase 3 NCT04917874 United States;
Oral erythromycin
Centre Hospitalier Universitaire de Nice
2011 Phase 3 NCT01340235 France;
POLYPHENON E
CHU de NICE
2010 - EUCTR2009-012750-21-FR France;
PTR-01
Phoenix Tissue Repair, Inc.
2020 Phase 2 NCT04599881 United States;
2019 Phase 1/Phase 2 NCT03752905 United States;
Palifermin
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Polyphenon E
Centre Hospitalier Universitaire de Nice
2010 Phase 2 NCT00951964 France;
Pregabalin
The Hospital for Sick Children
2019 Phase 3 NCT03928093 Canada;
Psorcutan-Ointment
Universitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität Salzburg
2016 Phase 2 EUCTR2016-001967-35-AT Austria;
QR-313
Phoenicis Therapeutics
2018 Phase 1/Phase 2 NCT03605069 France;Spain;United States;
QR-313 Gel for Topical (Cutaneous) Administration
ProQR Therapeutics
- Phase 1;Phase 2 EUCTR2017-004806-17-FR Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
ProQR Theraputics
2018 Phase 1;Phase 2 EUCTR2017-004806-17-ES Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
Wings Therapeutics Inc.
2018 Phase 1;Phase 2 EUCTR2017-004806-17-GB Czech Republic;France;Germany;Spain;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-004806-17-DE Czech Republic;France;Germany;Spain;United Kingdom;United States;
- Phase 1;Phase 2 EUCTR2017-004806-17-CZ Czech Republic;France;Germany;Spain;United Kingdom;United States;
REGE pro dressing
Egyptian Atomic Energy Authority
2017 - NCT03942250 Egypt;
RGN-137
Lenus Therapeutics, LLC
2019 Phase 2 NCT03578029 United States;
Rigosertib
Gemeinn. Salzburger Landeskliniken BetriebsGesmbH, University Hospital for Dermatology, EB-House Austria
2017 Phase 2 EUCTR2016-003832-19-AT Austria;
Rigosertib Oral Capsules / Rigosertib Intravenous
Prof. Johann Bauer
2021 Phase 1/Phase 2 NCT03786237 Austria;
Rigosertib Sodium
Thomas Jefferson University
2021 Early Phase 1 NCT04177498 United States;
Rituximab
Research group of rare intractable dermatologial disorder
2010 Phase 2 JPRN-UMIN000004428 Japan;
Ropivacaine
Assistance Publique - Hôpitaux de Paris
2017 - NCT03730584 France;
SASS
CHU de Quebec-Universite Laval
2019 Early Phase 1 NCT04171661 Canada;
SD-101
Scioderm INC, An Amicus Therapeutics Company
- Phase 3 EUCTR2014-002288-14-BE Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, An Amicus Therapeutics Company
2016 Phase 3 EUCTR2014-002288-14-LT Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-002288-14-PL Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-002288-14-DE Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-NL Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-GB Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-AT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, INC
2016 Phase 3 EUCTR2014-005679-96-ES Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-GB Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-AT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 - EUCTR2014-005679-96-NL Australia;Austria;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Scioderm, INC, An Amicus Therapeutics Company
2017 Phase 3 EUCTR2014-005679-96-LT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-DE Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
- Phase 3 EUCTR2014-005679-96-PL Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, INC.
2016 Phase 3 EUCTR2014-002288-14-ES Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-IT Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
SD-101 Dermal Cream ()
Scioderm, Inc.
2014 Phase 2 NCT02014376 United States;
SD-101 dermal cream ()
Scioderm, Inc.
2014 Phase 2 NCT02090283 United States;
2014 Phase 2 NCT02014376 United States;
SD-101-6.0 cream
Scioderm, Inc.
2015 Phase 3 NCT02670330 Australia;Austria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 NCT02384460 Australia;Austria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
SIN LV Mediated ex vivo transduced autologous fibroblasts expressing codon-optimised COL7A1
King's College London
2016 Phase 1 EUCTR2014-004884-19-GB United Kingdom;
SIN RV-mediated COL7A1 corrected autologous skin equivalent
INSERM
2019 Phase 1;Phase 2 EUCTR2016-002790-35-FR France;
See below for FCX-007 description)
Castle Creek Biosciences, LLC.
2020 Phase 3 NCT04213261 United States;
Sericare
Birken GmbH
2010 - EUCTR2010-019945-24-DE Germany;
Sericare®
Birken AG
2010 Phase 2 NCT01294241 Germany;
Serlopitant Tablet
Stanford University
2019 Phase 2 NCT03836001 United States;
SimpleCare
EB House Austria
2013 Phase 3 EUCTR2013-002034-21-AT Austria;
Sirolimus
Premier Specialists, Australia
2016 Phase 2 NCT03016715 Australia;
Sirolimus,
Stanford University
2016 Phase 2 NCT02960997 United States;
TC-MSC
King's College London
2015 Phase 1;Phase 2 EUCTR2014-004500-30-GB United Kingdom;
2012 Phase 1;Phase 2 EUCTR2012-001394-87-GB United Kingdom;
Universitair Medisch Centrum Utrecht
2014 Phase 2 EUCTR2012-000605-72-NL Netherlands;
Tacrolimus
Columbia University
2009 Early Phase 1 NCT00881556 United States;
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
Taltz
CHU NICE
2020 Phase 2 EUCTR2020-001542-19-FR France;
Tetracyclin
Rambam Health Care Campus
2006 Phase 4 NCT00336154 Israel;
Thymoglobulin
Masonic Cancer Center, University of Minnesota
2016 Phase 2 NCT02582775 United States;
TolaSure Topical Gel
BioMendics, LLC
2021 Phase 1 NCT05062070 United States;
Topical BPM31510 Cream
Shasa Hu
2016 Phase 1 NCT02793960 United States;
Topical Beremagene Geperpavec
Krystal Biotech, Inc.
2020 Phase 3 NCT04491604 United States;
Topical beremagene geperpavec
Krystal Biotech, Inc.
2018 Phase 2 NCT03536143 United States;
Topical opiod
Institute of Child Health
2005 Phase 4 NCT00231517 United Kingdom;
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL17A1-encoding retroviral vector
Holostem Terapie Avanzate s.r.l.
2017 Phase 1;Phase 2 EUCTR2016-000095-17-AT Austria;
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL7A1-encoding retroviral vector, obtained from secondary culture of ex vivo expanded autologous human keratinocytes.
Holostem Terapie Avanzate s.r.l.
2016 Phase 1;Phase 2 EUCTR2015-004592-74-AT Austria;
Transplantation
Holostem Terapie Avanzate s.r.l.
2022 Phase 2/Phase 3 NCT05111600 France;Germany;Italy;
Transvamix (100mg/mL THC, 50mg/mL CBD)
University Medical Center Groningen
- Phase 2 EUCTR2021-000103-20-NL Netherlands;
Trimethoprim
The Hospital for Sick Children
2006 Phase 2 NCT00380640 Canada;
Triterpene dry extract from birch cork
Birken GmbH
2010 - EUCTR2010-019945-24-DE Germany;
Unavailable
ProQR Therapeutics
- Phase 1;Phase 2 EUCTR2017-004806-17-FR Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
ProQR Theraputics
2018 Phase 1;Phase 2 EUCTR2017-004806-17-ES Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
Wings Therapeutics Inc.
2018 Phase 1;Phase 2 EUCTR2017-004806-17-GB Czech Republic;France;Germany;Spain;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-004806-17-DE Czech Republic;France;Germany;Spain;United Kingdom;United States;
- Phase 1;Phase 2 EUCTR2017-004806-17-CZ Czech Republic;France;Germany;Spain;United Kingdom;United States;
VPD-737
Jean Yuh Tang
2016 Phase 2 NCT02654483 United States;
Vehicle
Premier Specialists, Australia
2016 Phase 2 NCT03016715 Australia;
Stanford University
2016 Phase 2 NCT02960997 United States;
TWi Biotechnology, Inc.
2018 Phase 2 NCT03468322 Taiwan;
Vehicle (SD-101 )
Scioderm, Inc.
2014 Phase 2 NCT02014376 United States;
Vehicle Cream
InMed Pharmaceuticals Inc.
2021 Phase 2 NCT04908215 -
Vehicle Topical Gel
BioMendics, LLC
2021 Phase 1 NCT05062070 United States;
WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS
Medical University of Warsaw
2020 Phase 1;Phase 2 EUCTR2018-003890-91-PL Poland;
Zorblisa
Scioderm INC, An Amicus Therapeutics Company
- Phase 3 EUCTR2014-002288-14-BE Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, An Amicus Therapeutics Company
2016 Phase 3 EUCTR2014-002288-14-LT Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-002288-14-PL Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-002288-14-DE Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-NL Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-GB Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-AT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, INC
2016 Phase 3 EUCTR2014-005679-96-ES Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-GB Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-AT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 - EUCTR2014-005679-96-NL Australia;Austria;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Scioderm, INC, An Amicus Therapeutics Company
2017 Phase 3 EUCTR2014-005679-96-LT Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005679-96-DE Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
- Phase 3 EUCTR2014-005679-96-PL Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
Scioderm, INC.
2016 Phase 3 EUCTR2014-002288-14-ES Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-002288-14-IT Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;